ES2085905T3 - Preparacion solida de vitamina d3 activa que tiene mejor estabilidad. - Google Patents

Preparacion solida de vitamina d3 activa que tiene mejor estabilidad.

Info

Publication number
ES2085905T3
ES2085905T3 ES90903930T ES90903930T ES2085905T3 ES 2085905 T3 ES2085905 T3 ES 2085905T3 ES 90903930 T ES90903930 T ES 90903930T ES 90903930 T ES90903930 T ES 90903930T ES 2085905 T3 ES2085905 T3 ES 2085905T3
Authority
ES
Spain
Prior art keywords
solid preparation
better stability
active vitamin
activated
vitamin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90903930T
Other languages
English (en)
Inventor
Yuji Makino
Yoshiki Suzuki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Teijin Ltd
Original Assignee
Teijin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teijin Ltd filed Critical Teijin Ltd
Application granted granted Critical
Publication of ES2085905T3 publication Critical patent/ES2085905T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA INVENCION MUESTRA UNA PREPARACION SOLIDA ESTABILIZADA DE VITAMINA D3 ACTIVADA, QUE COMPRENDE UNA COMPOSICION D3 ACTIVADA DISPERSA EN UN EXCIPIENTE, QUE ES SOLUBLE EN UN DISOLVENTE ORGANICO, Y UNA SUSTANCIA BASE TAL COMO EL CITRATO SODICO U OXIDO DE MAGNESIO.
ES90903930T 1989-03-01 1990-02-28 Preparacion solida de vitamina d3 activa que tiene mejor estabilidad. Expired - Lifetime ES2085905T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1046571A JP2525478B2 (ja) 1989-03-01 1989-03-01 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤

Publications (1)

Publication Number Publication Date
ES2085905T3 true ES2085905T3 (es) 1996-06-16

Family

ID=12751003

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90903930T Expired - Lifetime ES2085905T3 (es) 1989-03-01 1990-02-28 Preparacion solida de vitamina d3 activa que tiene mejor estabilidad.

Country Status (10)

Country Link
US (1) US5158944A (es)
EP (1) EP0413828B1 (es)
JP (1) JP2525478B2 (es)
KR (2) KR930010621B1 (es)
AT (1) ATE136782T1 (es)
CA (1) CA2027592C (es)
DE (1) DE69026555T2 (es)
DK (1) DK0413828T3 (es)
ES (1) ES2085905T3 (es)
WO (1) WO1990009796A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02240024A (ja) * 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンｄ↓３類製剤用組成物
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
CA2061520C (en) * 1991-03-27 2003-04-22 Lawrence J. Daher Delivery system for enhanced onset and increased potency
DE69214704T2 (de) * 1991-04-09 1997-04-17 Takeda Chemical Industries Ltd Stabilisiertes Vitamin D Arzneimittel
HU227530B1 (en) * 1991-11-22 2011-07-28 Warner Chilcott Company Delayed-release compositions containing risedronate and process for their production
US6096342A (en) 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
WO1993012082A1 (fr) * 1991-12-11 1993-06-24 Central Glass Co., Ltd. Derive de 24,25-dihydroxyvitamine d¿3?
IL103224A (en) * 1992-09-18 1998-08-16 Teva Pharma Stabilized pharmaceutical compositions containing derivatives of vitamins d2 and d3
US6406714B1 (en) 1992-12-02 2002-06-18 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
US6103709A (en) * 1993-12-23 2000-08-15 The Regents Of The University Of California Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs and methods for treatment of vitamin D diseases
US6716454B2 (en) 1994-09-23 2004-04-06 Laboratorie Innothera, Société Anonyme Therapeutic combination of vitamin and calcium in unitary galenic tablet form, a method of obtaining it, and the use thereof
FR2724844B1 (fr) * 1994-09-23 1997-01-24 Innothera Lab Sa Association therapeutique vitamino-calcique, son procede d'obtention et son utilisation
US5698222A (en) * 1995-04-07 1997-12-16 Abbott Laboratories Calcium supplement
US6245805B1 (en) 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
AT408416B (de) * 1996-07-19 2001-11-26 Norbert Fuchs Pharmazeutische bzw. diätetische zusammensetzungen
FI120290B (fi) * 1996-12-30 2009-09-15 Mirador Res Oy Ltd Menetelmä, jonka avulla voidaan valmistaa sellaisia mausteseos-, ruoan ainesosa- ja elintarvikekoostumuksia, jotka alentavat seerumin kolesterolia
DE19710054A1 (de) * 1997-03-12 1998-09-17 Merck Patent Gmbh Pharmazeutische Zubereitung
AR024462A1 (es) 1999-07-01 2002-10-02 Merck & Co Inc Tabletas farmaceuticas
AU8252101A (en) * 2000-08-30 2002-03-13 Chugai Pharmaceutical Co Ltd Oct preparations
KR100688618B1 (ko) * 2001-09-12 2007-03-09 주식회사 유유 비타민 ｄ 경구투여용 서방성 약제 조성물
JP2005515996A (ja) * 2001-12-03 2005-06-02 ノバセア インコーポレイティッド 活性型ビタミンｄ化合物を含む薬学的組成物
US7148211B2 (en) * 2002-09-18 2006-12-12 Genzyme Corporation Formulation for lipophilic agents
US20040053895A1 (en) * 2002-09-18 2004-03-18 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20040058895A1 (en) * 2002-09-18 2004-03-25 Bone Care International, Inc. Multi-use vessels for vitamin D formulations
US20060189586A1 (en) * 2003-06-11 2006-08-24 Cleland Jeffrey L Pharmaceutical compositions comprising active vitamin D compounds
ES2593047T3 (es) 2006-02-03 2016-12-05 Opko Renal, Llc Tratamiento de la insuficiencia y deficiencia de vitamina D con 25-hidroxivitamina D2 y 25-hidroxivitamina D3
ES2670029T3 (es) 2006-06-21 2018-05-29 Opko Ireland Global Holdings, Ltd. Terapia usando agente de repleción de la vitamina D y agente de reemplazo de la hormona de la vitamina D
US11752158B2 (en) 2007-04-25 2023-09-12 Eirgen Pharma Ltd. Method of treating vitamin D insufficiency and deficiency
KR20190028822A (ko) 2007-04-25 2019-03-19 사이토크로마 인코포레이티드 비타민 ｄ 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
US20110038940A1 (en) * 2008-02-06 2011-02-17 Innov'ia Pulverulent composition and a process for preparing the same
WO2011123476A1 (en) 2010-03-29 2011-10-06 Cytochroma Inc. Methods and compositions for reducing parathyroid levels
EP2468265A3 (en) * 2010-12-04 2013-01-02 DEEF Pharmaceutical Industries Co. Homogeneous preparations containing vitamin D
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
JP7034595B2 (ja) * 2016-03-23 2022-03-14 株式会社ファンケル ビタミンｄ３安定化組成物
JP7032322B2 (ja) 2016-03-28 2022-03-08 オプコ アイルランド グローバル ホールディングス リミテッド ビタミンｄ治療法
JP6905538B2 (ja) * 2016-12-28 2021-07-21 中外製薬株式会社 Ｅｄ−７１の固体分散体および油分分散体を含む医薬組成物
US11638439B2 (en) * 2018-05-21 2023-05-02 Agthia Vitamin D-fortified water and method of manufacturing thereof
CN112368000B (zh) 2018-06-27 2024-08-27 中外制药株式会社 含有在油脂中包含ed-71及其环氧体的油分分散体的药物组合物
CN119236100B (zh) * 2023-06-25 2025-08-19 广州朗圣药业有限公司 一种维生素d3包合物及其制剂、制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2195596A (en) * 1936-11-07 1940-04-02 Squibb & Sons Inc Protected-vitamin-containing tablet
US2691619A (en) * 1951-09-18 1954-10-12 Pfizer & Co C Fat-soluble vitamin-containing products and process therefor
DE1492034A1 (de) * 1965-05-18 1969-02-20 Merck Ag E Verfahren zur Herstellung fester haltbarer Zubereitungen von empfindlichen,in Wasser schwer loeslichen Wirkstoffen,vorzugsweise Arzneimitteln
US3901928A (en) * 1973-01-10 1975-08-26 Robert Henry Hesse 1' ,3' -dihydroxy steroid-5-enes method of preparing same and their use for preparing 1' -hydroxy-25-hydrogen vitamin d compounds
JPS5418330B2 (es) * 1973-03-16 1979-07-06
DE2400819C2 (de) * 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
JPS51128417A (en) * 1975-04-28 1976-11-09 Teijin Ltd A method for stabilizing active vitamin d3 derivatives
US4069321A (en) * 1975-10-14 1978-01-17 Merck & Co., Inc. Blocked cholecalciferol and dihydrotachysterol 3 derivatives
JPS5740415A (en) * 1980-08-25 1982-03-06 Teijin Ltd Novel active type vitamin d3 derivative composition
JPS5740461A (en) * 1980-08-25 1982-03-06 Teijin Ltd Novel activated vitamin d3 derivative composition
JPS5740414A (en) * 1980-08-25 1982-03-06 Teijin Ltd Novel active type vitamin d3 derivative composition
US4308264A (en) * 1981-01-28 1981-12-29 Abbott Laboratories Stabilized, dilute aqueous preparation of 1α,25-dihydroxycholecalciferol for neonatal administration
US4652405A (en) * 1981-08-28 1987-03-24 Hoffman-La Roche Inc. Synthesis of 1α,25-dihydroxy-24R-fluorocholecalciferol and 1α,25-dihydroxy-24S-fluorocholecalciferol
US4617297A (en) * 1982-02-12 1986-10-14 Hoffmann-La Roche Inc. Method of treating disease states by the administration of 1α,25,26-trihydroxycholecalciferol
JPS58206533A (ja) * 1982-05-27 1983-12-01 Teijin Ltd 活性型ビタミンｄ↓３誘導体組成物及びそれを活性成分とする薬剤
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
JPS6141351A (ja) * 1984-07-31 1986-02-27 日産自動車株式会社 空気噴射式織機の緯糸端部処理装置
JPS6144860A (ja) * 1984-08-10 1986-03-04 Taisho Pharmaceut Co Ltd １α．２５−ジヒドロキシ−２６．２７−ジメチルビタミンＤ↓３
US4613594A (en) * 1984-11-16 1986-09-23 Hoffmann-La Roche Inc. Fluorinated vitamin D3 compounds
JPS6217A (ja) * 1985-02-14 1987-01-06 Chugai Pharmaceut Co Ltd 安定な活性型ビタミンｄ３類製剤
JPS6251948A (ja) * 1985-07-23 1987-03-06 廖　阿亮 デコレーション用プレザープとその製造方法
JPH0635442B2 (ja) * 1985-08-28 1994-05-11 住友精化株式会社 チオカルバメ−ト誘導体の製造法
JPS62149619A (ja) * 1985-09-05 1987-07-03 Teijin Ltd 活性型ビタミンｄ３類注射用組成物
JPS6346728A (ja) * 1986-08-15 1988-02-27 Hitachi Electronics Eng Co Ltd ランプ電源制御方式および制御回路
JPS6425723A (en) * 1988-07-07 1989-01-27 Teijin Ltd Production of active type vitamin d3 composition

Also Published As

Publication number Publication date
CA2027592C (en) 1996-11-26
ATE136782T1 (de) 1996-05-15
JP2525478B2 (ja) 1996-08-21
WO1990009796A1 (en) 1990-09-07
JPH02229115A (ja) 1990-09-11
KR930010621B1 (ko) 1993-11-02
EP0413828A4 (en) 1991-10-30
CA2027592A1 (en) 1990-09-02
US5158944A (en) 1992-10-27
EP0413828A1 (en) 1991-02-27
KR920700036A (ko) 1992-02-19
DK0413828T3 (da) 1996-05-13
DE69026555D1 (de) 1996-05-23
DE69026555T2 (de) 1996-09-19
EP0413828B1 (en) 1996-04-17

Similar Documents

Publication Publication Date Title
ES2085905T3 (es) Preparacion solida de vitamina d3 activa que tiene mejor estabilidad.
DE69031219D1 (de) Stabile zusammensetzungen von askorbinsäure
FI863652A0 (fi) 7-isopropoxiisflavoninklusionskomplex bildat med cyklodextrin och ett foerfarande foer dess framstaellning.
DK25587A (da) Toer, stabiliseret, partikelformig, fritstroemmende tocopherolsammensaetning
FR2634376B1 (fr) Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
NO842291L (no) Fremgangsmaate for fremstilling av orale antidiabetiske substanser.
NO171443C (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende syntetiske lipider
DE69812343D1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
EP0645145A3 (en) Stabilized drugs and stabilizing solvent.
DK653688A (da) Stabiliserede laegemiddelaktive forbindelser, fremgangsmaade til deres frmstilling samt stabile laegemiddelpraeparater
ES2134359T3 (es) Composiciones viscoelasticas de compuestos organicos fluorados.
PT77898B (en) Process for the preparation of substituted 4-amino-methylenochromanes and 4-aminomethylenecromenes acting on the blood circulation and application thereof in the preparation of pharmaceutical compositions acting on the blood circulation
MX9203320A (es) Composicion antialergica que contiene compuestos biciclicos switterionicos.
DE69414904D1 (de) Silikat-Polymer enthaltende pharmazeutische Zusammensetzungen
KR840005024A (ko) 제약혼합물제제 및 그 제조방법
BR0015939A (pt) Sistemas terapêuticos transdérmicos com estabilidade aperfeiçoada e um processo para a sua preparação
DE58905681D1 (de) Pharmazeutische Präparate zur verbesserten Resorption antibakterieller Verbindungen.
SE8803935L (sv) Laekemedelskomposition
ATE110269T1 (de) Ipriflavone enthaltende pharmazeutische zubereitungen, verfahren zur herstellung und therapeutische verwendung.
ATE128114T1 (de) Enzymatische auflösungssysteme und in diesen systemen angewandte verbindungen und ihre herstellungen.
IL82523A (en) Pharmaceutical composition comprising a surface-active compound and fluorinated compound capable of emitting ionic fluorine for inhibiting or destroying a unicellular living being or virus and inhibiting or destroying an enzyme associated with the being or virus
KR910005886A (ko) 안정화 백혈구 인터페론
KR930012023A (ko) 환원된 형태의 비글리코실화 재조합 인체 il2의 안정화된 제약 조성물 및 그의 제조방법
ES2043959T3 (es) Preparado farmaceutico estabilizado, que contiene n-acetilcisteina.
DE3871047D1 (de) Zusammensetzungen mit dichlortrifluorethan.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 413828

Country of ref document: ES